- Home
- INTU vs NVO Comparison
INTU vs NVO Comparison
Compare INTU & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTU | NVO |
|---|---|---|
| Founded | 1983 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7B | 212.7B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | INTU | NVO |
|---|---|---|
| Price | $675.21 | $52.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 11 |
| Target Price | ★ $811.72 | $54.25 |
| AVG Volume (30 Days) | 1.8M | ★ 16.1M |
| Earning Date | 11-20-2025 | 02-04-2026 |
| Dividend Yield | 0.71% | ★ 2.34% |
| EPS Growth | ★ 41.77 | 10.06 |
| EPS | ★ 14.57 | 3.67 |
| Revenue | $19,433,000,000.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $14.85 | $7.77 |
| Revenue Next Year | $12.47 | $1.86 |
| P/E Ratio | $46.30 | ★ $14.25 |
| Revenue Growth | ★ 17.14 | 16.64 |
| 52 Week Low | $532.65 | $43.08 |
| 52 Week High | $813.70 | $93.80 |
Technical Indicators
Market Signals| Indicator | INTU | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 62.78 |
| Support Level | $666.40 | $47.59 |
| Resistance Level | $679.26 | $48.80 |
| Average True Range (ATR) | 14.15 | 1.19 |
| MACD | 1.98 | 0.49 |
| Stochastic Oscillator | 81.86 | 85.50 |
Price Performance
Historical ComparisonAbout INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.